Medulloblastoma-Biology and microenvironment: A review

Pediatric Hematology and Oncology

Volumn 29, Issue 6, 2012, Pages 495-506

  Byrd, Tiara ^a   Grossman, Robert G ^b   Ahmed, Nabil ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Brain; Medulloblastoma; Microenvironment; Review; Therapy

Indexed keywords

APC PROTEIN; AXIN; BETA CATENIN; CHEMOKINE RECEPTOR CXCR4; DNA METHYLTRANSFERASE INHIBITOR; INTERLEUKIN 8; NEUROTROPHIN 3; PROTEIN P53; PROTEIN PATCHED 1; PROTEIN TYROSINE KINASE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; WNT PROTEIN;

ANGIOGENESIS; BRAIN CANCER; BREAST CANCER; CANCER STEM CELL; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; CHROMOSOME ABERRATION; COLON CANCER; CYTOMEGALOVIRUS; EMBRYO DEVELOPMENT; EPIGENETICS; FAMILIAL CANCER; GENE AMPLIFICATION; GENE MUTATION; GENE SILENCING; GENOMIC INSTABILITY; HAPLOINSUFFICIENCY; HOMEOSTASIS; HUMAN; IMMUNOCOMPETENT CELL; ISOCHROMOSOME; JC VIRUS; MEDULLOBLASTOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; ONCOGENE MYC; PLEIOTROPY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; TURCOT SYNDROME; WNT SIGNALING PATHWAY;

EID: 84865340252     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2012.698372     Document Type: Review

References (90)

1. Santarius T, Shipley J, Brewer D, Stratton MR, Cooper CS. A census of amplified and overexpressed human cancer genes. Nat Rev Cancer. Jan 2010;10(1):59-64.
2. Ryan SL, Schwalbe EC, Cole M, et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol. 2012;123:501-513.
3. Korshunov A, Remk M, Kool M, et al. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathol. 2012;123:515-527.
4. Lindberg E, Persson A, Ora I, et al. Concurrent gain of 17q and the MYC oncogene in a medullomyoblastoma. Neuropathology. Dec 2007;27(6):556-560. (Pubitemid 350045672)
5. Whitfield JR, Soucek L. Tumor microenvironment: becoming sick of Myc. Cell Mol Life Sci. Oct 28 2012;69:931-934.
6. Breit S, Ashman K, Wilting J, et al. The N-myc oncogene in human neuroblastoma cells: down-regulation of an angiogenesis inhibitor identified as activin A. Cancer Res. Aug 15 2000; 60(16):4596-4601. (Pubitemid 32103645)
7. Noujaim D, van Golen CM, van Golen KL, et al. N-Myc and Bcl-2 coexpression induces MMP-2 secretion and activation in human neuroblastoma cells. Oncogene. Jul 4 2002;21(29):4549-4557. (Pubitemid 34785731)
8. Oikawa M, Yoshiura K, Kondo H, et al. Significance of genomic instability in breast cancer in atomic bomb survivors: analysis of microarray-comparative genomic hybridization. Radiat Oncol. 2011;6:168.
9. Castellino RC, De Bortoli M, Lu X, et al. Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neurooncol. Feb 2008;86(3):245-256.
10. Fuller C, Fouladi M, Gajjar A, et al. Chromosome 17 abnormalities in pediatric neuroblastic tumor with abundant neuropil and true rosettes. Am J Clin Pathol. Aug 2006;126(2):277-283. (Pubitemid 44162575)
11. Biegel JA, Burk CD, Barr FG, Emanuel BS. Evidence for a 17p tumor related locus distinct from p53 in pediatric primitive neuroectodermal tumors. Cancer Res. Jun 15 1992;52(12):3391-3395.
12. Pan E, Pellarin M, Holmes E, et al. Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin Cancer Res. Jul 1 2005;11(13):4733-4740. (Pubitemid 41557192)
13. NamDH,WangKC,KimYM,et al.Theeffect of isochromosome17q presence, proliferative and apoptotic indices, expression of c-erbB-2, bcl-2 and p53 proteins on the prognosis ofmedulloblastoma. J Korean Med Sci. Aug 2000;15(4):452-456.
14. Loda M, Giangaspero F, Badiali M, et al. p53 gene expression in medulloblastoma by quantitative polymerase chain reaction. DiagnMol Pathol.Mar 1992;1(1):36-44.
15. Gilbertson RJ. Medulloblastoma: signalling a change in treatment. Lancet Oncol. Apr 2004;5(4):209-218. (Pubitemid 38391216)
16. Rous P. A Transmissible avian neoplasm. (Sarcoma of the common fowl.). J Exp Med. Sep 1 1910;12(5):696-705.
17. Rous P. A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J Exp Med. Apr 1 1911;13(4):397-411.
18. Murphy JB, Rous P. The behavior of Chicken Sarcoma implanted in the developing embryo. J Exp Med. Feb 1 1912;15(2):119-132.
19. Rubin H, Temin HM. Infection with the Rous sarcoma virus in vitro. Fed Proc. Dec 1958;17(4):994-1003.
20. Temin HM, Rubin H. Characteristics of an assay for Rous sarcoma virus and Rous sarcoma cells in tissue culture. Virology. Dec 1958;6(3):669-688.
21. Tarpley WG, Temin HM. The location of v-src in a retrovirus vector determines whether the virus is toxic or transforming.Mol Cell Biol. Dec 1984;4(12):2653-2660. (Pubitemid 15113603)
22. Garcia De Viedma D, Diaz Infantes M, Miralles P, et al. JC virus load in progressive multifocal leukoencephalopathy: analysis of the correlation between the viral burden in cerebrospinal fluid, patient survival, and the volume of neurological lesions. Clin Infect Dis. Jun 15, 2002;34(12):1568-1575. (Pubitemid 34615441)
23. Caracciolo V, Reiss K, Khalili K, et al. Role of the interaction between large T antigen and Rb family members in the oncogenicity of JC virus. Oncogene. Aug 28 2006;25(38):5294-5301. (Pubitemid 44299090)
24. Felsani A,Mileo AM, Paggi MG. Retinoblastoma family proteins as key targets of the smallDNA virus oncoproteins. Oncogene. Aug 28 2006;25(38):5277-5285. (Pubitemid 44299088)
25. Bollag B, Prins C, Snyder EL, Frisque RJ. Purified JC virus T and T' proteins differentially interactwith the retinoblastoma family of tumor suppressor proteins. Virology. Aug 15 2000;274(1):165-178. (Pubitemid 30650691)
26. Howard CM, Claudio PP, De Luca A, et al. Inducible pRb2/p130 expression and growth-suppressive mechanisms: evidence of a pRb2/p130, p27Kip1, and cyclin E negative feedback regulatory loop. Cancer Res.May 15 2000;60(10):2737-2744. (Pubitemid 30318252)
27. White MK, Khalili K. Interaction of retinoblastoma protein family members with large T-antigen of primate polyomaviruses. Oncogene. Aug 28 2006;25(38):5286-5293. (Pubitemid 44299089)
28. Caracciolo V, Reiss K, Crozier-Fitzgerald C, et al. Interplay between the retinoblastoma related pRb2/p130 and E2F-4 and -5 in relation to JCV-TAg. J Cell Physiol. Jul 2007;212(1):96-104. (Pubitemid 46867591)
29. Del Valle L, Baehring J, Lorenzana C, et al. Expression of a human polyomavirus oncoprotein and tumour suppressor proteins inmedulloblastomas. Mol Pathol. Oct 2001;54(5):331-337. (Pubitemid 32928260)
30. Takakura K, InoyaH,Nagashima K, et al.Viral neurooncogenesis. ProgExpTumorRes. 1987;30:10-20.
31. Caracciolo V,MacalusoM,D'Agostino L, et al. Cross-talk between T-Ag presence and pRb family and p53/p73 signaling in mouse and humanmedulloblastoma. J Cell Biochem.May 2010;110(1):182-190.
32. Zu Rhein GM. Studies of JC virus-induced nervous system tumors in the Syrian hamster: a review. Prog Clin Biol Res. 1983;105:205-221.
33. Padgett BL,Walker DL, ZuRhein GM, Varakis JN.Differential neurooncogenicity of strains of JCvirus, a human polyoma virus, in newborn Syrian hamsters. Cancer Res.Mar 1977;37(3):718-720. (Pubitemid 8051633)
34. Krynska B, Otte J, Franks R, et al. Human ubiquitous JCV(CY) T-antigen gene induces brain tumors in experimental animals. Oncogene. Jan 7 1999;18(1):39-46. (Pubitemid 29060577)
35. Munoz-Marmol AM,Mola G, Ruiz-Larroya T, et al. Rarity of JC virus DNA sequences and early proteins in human gliomas and medulloblastomas: the controversial role of JC virus in human neurooncogenesis. Neuropathol Appl Neurobiol. Apr 2006;32(2):131-140.
36. Vasishta RK, Pasricha N, Nath A, Sehgal S.The absence of JC virus antigens in Indian children with medulloblastomas. Indian J Pathol Microbiol. Jan-Mar 2009;52(1):42-45.
37. Krynska B, Del Valle L, Croul S, et al. Detection of human neurotropic JC virus DNA sequence and expression of the viral oncogenic protein in pediatric medulloblastomas. Proc Natl Acad Sci U S A. Sep 28 1999;96(20):11519-11524. (Pubitemid 29487413)
38. Weggen S, Bayer TA, von Deimling A, et al. Low frequency of SV40, JC and BK polyomavirus sequences in human medulloblastomas, meningiomas and ependymomas. Brain Pathol. Jan 2000;10(1):85-92. (Pubitemid 30056396)
39. Pereira L, Maidji E, Fisher SJ, et al. HCMV persistence in the population: potential transplacental transmission. In: Arvin A, Campadelli-Fiume G,Mocarski E, et al., eds. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press, 2007.
40. Shimamura M, Murphy-Ullrich JE, Britt WJ. Human cytomegalovirus induces TGF-beta1 activation in renal tubular epithelial cells after epithelial-to-mesenchymal transition. PLoS Pathog. 2010;6(11):e1001170. doi:10.1371/journal.ppat.1001170.
41. Cobbs CS, Soroceanu L, Denham S, et al. Human cytomegalovirus induces cellular tyrosine kinase signaling and promotes glioma cell invasiveness. J Neurooncol. Dec 2007;85(3):271-280. (Pubitemid 350142516)
42. Zhu Y, Huang L, Anders DG. Human cytomegalovirus oriLyt sequence requirements. J Virol. Jun 1998;72(6):4989-4996. (Pubitemid 28215679)
43. Straat K, Liu C, Rahbar A, et al. Activation of telomerase by human cytomegalovirus. J Natl Cancer Inst. Apr 1 2009;101(7):488-497.
44. Baryawno N, Rahbar A, Wolmer-Solberg N, et al. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clin Invest. Oct 2011;121(10):4043-4055.
45. Karbowniczek M, Cash T, Cheung M, et al. Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. J Biol Chem. Jul 16 2004;279(29):29930-29937. (Pubitemid 38937912)
46. Koch A, Hrychyk A,Hartmann W, et al.Mutations of theWnt antagonist AXIN2 (Conductin) result in TCF-dependent transcription in medulloblastomas. Int J Cancer. Jul 15 2007;121(2):284-291. (Pubitemid 46917696)
47. Rubenfeld M, Abramson DH, Ellsworth RM, Kitchin FD. Unilateral vs. bilateral retinoblastoma. Correlations between age at diagnosis and stage of ocular disease. Ophthalmology. Aug 1986;93(8):1016-1019. (Pubitemid 16012707)
48. Rausch T, Jones DT, Zapatka M, et al. Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53Mutations. Cell. Jan 20 2012;148(1-2):59-71.
49. Pfaff E, RemkeM, Sturm D, et al. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol. Dec 10 2010;28(35):5188-5196.
50. Rieber J, RemkeM, Hartmann C, et al. Novel oncogene amplifications in tumors from a family with Li-Fraumeni syndrome. Genes Chromosomes Cancer. Jul 2009;48(7):558-568.
51. EichenmullerM, Bauer R, Von Schweinitz D, et al. Hedgehog-independent overexpression of transforming growth factor-beta1 in rhabdomyosarcoma of Patched1 mutant mice. Int J Oncol. Aug 2007;31(2):405-412.
52. Rice JM. Inducible and transmissible genetic events and pediatric tumors of the nervous system. J Radiat Res (Tokyo). 2006;47 Suppl B:B1-11.
53. Cowan R, Hoban P, Kelsey A, et al.Thegene for the naevoid basal cell carcinoma syndrome acts as a tumour-suppressor gene inmedulloblastoma. Br J Cancer. 1997;76(2):141-145. (Pubitemid 27279651)
54. Calzada-Wack J, Kappler R, Schnitzbauer U, et al. Unbalanced overexpression of themutant allele in murine Patchedmutants. Carcinogenesis.May 2002;23(5):727-733. (Pubitemid 34567510)
55. Wetmore C, Eberhart DE, Curran T. The normal patched allele is expressed in medulloblastomas from mice with heterozygous germ-line mutation of patched. Cancer Res. Apr 15 2000;60(8):2239-2246. (Pubitemid 30225189)
56. ZurawelRH, AllenC,Wechsler-Reya R, et al. Evidence that haploinsufficiency of Ptch leads to medulloblastoma in mice. Genes Chromosomes Cancer.May 2000;28(1):77-81. (Pubitemid 30176765)
57. Hamilton SR, Liu B, Parsons RE, et al.The molecular basis of Turcot's syndrome. N Engl J Med. Mar 30 1995;332(13):839-847.
58. Lindsey JC, Lusher ME, Anderton JA, et al. Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling. Carcinogenesis. May 2004;25(5):661-668. (Pubitemid 38618517)
59. Crawford JR, MacDonald TJ, Packer RJ. Medulloblastoma in childhood: new biological advances. Lancet Neurol. Dec 2007;6(12):1073-1085. (Pubitemid 350116703)
60. Gajjar A, Hernan R, Kocak M, et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol. Mar 15 2004;22(6):984-993. (Pubitemid 41095029)
61. Gilbertson RJ. ERBB2 in pediatric cancer: innocent until proven guilty. Oncologist. Aug 2005;10(7):508-517. (Pubitemid 41266332)
62. Ahmed N, Ratnayake M, Savoldo B, et al. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. Jun 15 2007;67(12):5957-5964. (Pubitemid 46985032)
63. Gulino A, Arcella A, Giangaspero F. Pathological and molecular heterogeneity of medulloblastoma. Curr Opin Oncol. Nov 2008;20(6):668-675.
64. Paget S.The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. Aug 1989;8(2):98-101.
65. Fokas E, Engenhart-Cabillic R, Daniilidis K, et al.Metastasis: the seed and soil theory gains identity. Cancer Metastasis Rev. Dec 2007;26(3-4):705-715. (Pubitemid 350115118)
66. Weber CE, Kuo PC. The tumormicroenvironment. Surg Oncol. Sep 29 2011.
67. Witz IP.The tumor microenvironment: themaking of a paradigm. Cancer Microenviron. Sep 2009;2 Suppl 1:9-17.
68. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. Apr 2009;9(4):239-252.
69. HanahanD,Weinberg RA.Hallmarks of cancer: the next generation. Cell.Mar 4 2011;144(5):646-674.
70. Bates RC, Mercurio AM. The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol Ther. Apr 2005;4(4):365-370. (Pubitemid 41351251)
71. Salsman VS, Chow KK, Shaffer DR, et al. Crosstalk between medulloblastoma cells and endothelium triggers a strong chemotactic signal recruiting T lymphocytes to the tumormicroenvironment. PLoS One. 2011;6(5):e20267.
72. Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol.May 2002;282(5):C947-970.
73. Moses MA. The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells. 1997;15(3):180-189. (Pubitemid 27225283)
74. Xian X, Hakansson J, Stahlberg A, et al. Pericytes limit tumor cell metastasis. J Clin Invest. Mar 2006;116(3):642-651. (Pubitemid 43326873)
75. Unemori EN, FerraraN,Bauer EA,Amento EP.Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol. Dec 1992;153(3):557-562.
76. Kimura H, Weisz A, Ogura T, et al. Identification of hypoxia-inducible factor 1 ancillary sequence and its function in vascular endothelial growth factor gene induction by hypoxia and nitric oxide. J Biol Chem. Jan 19 2001;276(3):2292-2298. (Pubitemid 32109715)
77. Slongo ML,Molena B, Brunati AM, et al. Functional VEGF and VEGF receptors are expressed in humanmedulloblastomas. Neuro Oncol. Oct 2007;9(4):384-392.
78. Tural S, Gercek A, Konya D, et al. Microvessel density and vascular endothelial growth factor expression as predictors of childrens' survival from cerebellar medulloblastoma. J Clin Neurosci. Sep 2009;16(9):1199-1202.
79. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. Jan 2006;6(1):24-37. (Pubitemid 43053650)
80. Deschoolmeester V, Baay M, VanMarck E, et al. Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol. 2010;11:19.
81. Ruffell B, Au A, Rugo HS, et al. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A. Aug 8 2012;109:2796-2801.
82. Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol. Nov 1 2010;185(9):4977-4982.
83. Gonzalez-Martin A, Gomez L, Lustgarten J, et al. Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells. Cancer Res. Aug 15 2011;71(16):5455-5466.
84. Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev. Feb 2008;18(1):11-18. (Pubitemid 351694442)
85. Wakabayashi O, Yamazaki K, Oizumi S, et al.CD4+T cells in cancer stroma, not CD8+T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci. Nov 2003;94(11):1003-1009. (Pubitemid 37521216)
86. Vincent S,MirshariM,Nicolas C, et al. Large-cellmedulloblastomawith arrestin-like protein expression. Clin Neuropathol. Jan-Feb 2003;22(1):1-9.
87. Salama P, Phillips M, Grieu F, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. Jan 10 2009;27(2):186-192.
88. Zhou P, ShaH, Zhu J.Therole of T-helper 17 (Th17) cells in patientswith medulloblastoma. J Int Med Res.Mar-Apr 2010;38(2):611-619.
89. Wiegering V, Eyrich M, Rutkowski S, et al. TH1 predominance is associated with improved survival in pediatricmedulloblastoma patients. Cancer Immunol Immunother.May 2011;60(5):693-703.
90. AhmedN, Salsman VS, Kew Y, et al.HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res. Jan 15 2010;16(2):474-485.